Brokerages Set Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) PT at $31.14

Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) has received an average recommendation of “Buy” from the seven analysts that are presently covering the firm, MarketBeat Ratings reports. Seven investment analysts have rated the stock with a buy recommendation. The average 1-year price target among brokerages that have issued ratings on the stock in the last year is $31.14.

Several research firms have recently commented on CPRX. Truist Financial lifted their price target on shares of Catalyst Pharmaceuticals from $30.00 to $36.00 and gave the company a “buy” rating in a research report on Monday, November 11th. Stephens began coverage on Catalyst Pharmaceuticals in a research report on Monday, November 18th. They issued an “overweight” rating and a $35.00 target price on the stock. HC Wainwright reiterated a “buy” rating and set a $30.00 price target on shares of Catalyst Pharmaceuticals in a report on Friday, November 8th. Finally, StockNews.com raised Catalyst Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research report on Friday.

Insider Buying and Selling at Catalyst Pharmaceuticals

In other Catalyst Pharmaceuticals news, insider Gary Ingenito sold 12,000 shares of the business’s stock in a transaction on Wednesday, November 27th. The shares were sold at an average price of $22.72, for a total value of $272,640.00. Following the completion of the transaction, the insider now owns 51,391 shares in the company, valued at $1,167,603.52. The trade was a 18.93 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website. Also, Director Molly Harper sold 17,500 shares of the company’s stock in a transaction on Wednesday, November 27th. The stock was sold at an average price of $22.00, for a total value of $385,000.00. The disclosure for this sale can be found here. Insiders sold a total of 79,500 shares of company stock valued at $1,754,140 in the last three months. 11.00% of the stock is owned by corporate insiders.

Hedge Funds Weigh In On Catalyst Pharmaceuticals

Several hedge funds and other institutional investors have recently made changes to their positions in the stock. GAMMA Investing LLC lifted its stake in Catalyst Pharmaceuticals by 62.1% in the third quarter. GAMMA Investing LLC now owns 1,778 shares of the biopharmaceutical company’s stock worth $35,000 after acquiring an additional 681 shares during the last quarter. nVerses Capital LLC purchased a new stake in shares of Catalyst Pharmaceuticals during the 3rd quarter worth $50,000. Larson Financial Group LLC grew its stake in shares of Catalyst Pharmaceuticals by 27,218.2% during the third quarter. Larson Financial Group LLC now owns 3,005 shares of the biopharmaceutical company’s stock worth $60,000 after purchasing an additional 2,994 shares in the last quarter. Meeder Asset Management Inc. purchased a new position in Catalyst Pharmaceuticals in the second quarter valued at $70,000. Finally, Quantbot Technologies LP acquired a new stake in Catalyst Pharmaceuticals in the third quarter valued at $151,000. Hedge funds and other institutional investors own 79.22% of the company’s stock.

Catalyst Pharmaceuticals Trading Down 1.0 %

Catalyst Pharmaceuticals stock opened at $21.31 on Wednesday. The stock has a market cap of $2.54 billion, a P/E ratio of 18.06, a PEG ratio of 3.35 and a beta of 0.79. The company has a 50-day moving average price of $21.80 and a 200 day moving average price of $19.77. Catalyst Pharmaceuticals has a 12-month low of $13.12 and a 12-month high of $24.27.

About Catalyst Pharmaceuticals

Catalyst Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); and Ruzurgi for the treatment of pediatric LEMS patients.